Sionna Therapeutics (NASDAQ:SION) Announces Earnings Results

Sionna Therapeutics (NASDAQ:SION) announced its quarterly earnings data on Thursday. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.02), FiscalAI reports.

Sionna Therapeutics Trading Up 4.8%

SION traded up $2.27 during trading on Thursday, hitting $49.61. 778,269 shares of the company traded hands, compared to its average volume of 601,903. The company has a market cap of $2.24 billion, a PE ratio of -25.70 and a beta of 1.33. The stock’s 50-day simple moving average is $42.18 and its two-hundred day simple moving average is $40.33. Sionna Therapeutics has a 1 year low of $16.87 and a 1 year high of $51.91.

Insider Activity

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at $123,491,612.84. The trade was a 6.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 184,639 shares of Sionna Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the transaction, the director owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 892,538 shares of company stock valued at $40,656,209. 5.10% of the stock is currently owned by company insiders.

Institutional Trading of Sionna Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SION. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics during the 4th quarter valued at $26,290,000. Vanguard Group Inc. grew its holdings in Sionna Therapeutics by 81.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after acquiring an additional 512,803 shares in the last quarter. State Street Corp grew its holdings in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after acquiring an additional 453,196 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares in the last quarter. Finally, Viking Global Investors LP raised its holdings in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have commented on SION shares. Freedom Capital lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Citizens Jmp restated a “market outperform” rating and issued a $63.00 target price on shares of Sionna Therapeutics in a research note on Tuesday, May 26th. Wall Street Zen downgraded Sionna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Finally, Stifel Nicolaus raised their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Sionna Therapeutics has an average rating of “Moderate Buy” and an average price target of $53.89.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.